| abstract |
The present invention relates to a composition for preventing or treating nonalcoholic fatty liver, comprising loganin as an active ingredient. According to the present invention, loganin inhibits NLRP3 inflammasome activity by reducing inflammatory factors, and inflammatory macrophages. , neutrophils, total macrophages, triglycerides, and collagen deposition to suppress liver inflammation, fat accumulation and fibrosis, Loganin having the above effects is a pharmaceutical composition for preventing or treating non-alcoholic fatty liver, non-alcoholic fatty liver prevention Or it may be usefully used as a health food composition for improvement. |